The agreement – financial terms of which were not made public – covers the distribution of Pfizer’s renal cell carcinoma treatment Inlyta (axitinib), which was approved by the US Food and Drug Administration (FDA) late last month.
Stuart Frantz, CEO of Cary, North Carolina-based Biologics Inc, said: “It’s an honour to be selected as a Limited Distribution Network partner for Pfizer’s Inlyta,” adding that “We are committed to delivering the highest standard of care to patients and are excited to partner with Pfizer in providing another option to patients battling renal cell carcinoma.”
Pfizer joins top tier biopharmas like Genentech and AstraZeneca as users of Biologics’ cancer drugs distribution service.